Trial: 202006136

A Phase 1, Multicenter, Open-Label Study to Determine the Safety,
Tolerability, Pharmacokinetics, and Preliminary Efficacy of Combinations
of ABBV-927 with ABBV-368, Budigalimab (ABBV-181) and/or
Chemotherapy in Subjects with Locally Advanced or Metastatic Solid
Tumors

Phase

I

Principal Investigator

Opyrchal, Mateusz

Disease Site

Anus; Bones and Joints; Breast; Cervix; Colon; Corpus Uteri; Esophagus; Eye and Orbit; Ill-Defined Sites; Kidney; Larynx; Lip, Oral Cavity and Pharynx; Liver; Lung; Melanoma, Skin; Other Digestive Organ; Other Endocrine System; Other Female Genital; Other Male Genital; Other Respiratory and Intrathoracic Organs; Other Skin; Other Urinary; Ovary; Pancreas; Prostate; Rectum; Small Intestine; Soft Tissue; Stomach; Thyroid; Unknown Sites; Urinary Bladder

Learn more about this study at: clinicaltrials.gov